Core Insights - Orion Pharma has initiated a Phase 2 trial for ODM-212, an oral pan-TEAD inhibitor, targeting malignant pleural mesothelioma (MPM) and epithelioid hemangioendothelioma (EHE), both of which are rare and challenging cancers to treat [1][2][3] Trial Details - The TEADES trial is a multi-center, open-label study enrolling approximately 300 patients with MPM, EHE, or other solid tumors with Hippo pathway dysfunction, focusing on those who have progressed after standard treatments [2] - Primary endpoints include safety and tolerability, while secondary endpoints encompass Overall Response Rate, Progression Free Survival, and Overall Survival [2] Drug Mechanism and Development - ODM-212 functions as a pan-TEAD inhibitor, targeting the Hippo signaling pathway to prevent uncontrolled tumor growth and resistance to therapies by blocking TEAD transcription factors [4] - The first patient was treated in December 2025, marking a significant milestone in the clinical development of ODM-212 [1][3] Cancer Background - Malignant Pleural Mesothelioma (MPM) accounts for 80-90% of mesothelioma cases and is primarily linked to asbestos exposure, with current treatments being limited to chemotherapy and immunotherapy [5] - Epithelioid Hemangioendothelioma (EHE) is an ultra-rare vascular tumor with no standard treatment available, affecting less than one per million people [6] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience, focusing on developing, manufacturing, and marketing pharmaceuticals and active ingredients, particularly in oncology and pain management [8]